MX2009011275A - Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma. - Google Patents
Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma.Info
- Publication number
- MX2009011275A MX2009011275A MX2009011275A MX2009011275A MX2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A MX 2009011275 A MX2009011275 A MX 2009011275A
- Authority
- MX
- Mexico
- Prior art keywords
- glucose
- formulation
- controlled release
- composition suitable
- microsphere composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se describen las microesferas biodegradables capaces de liberar un péptido regulador de la glucosa de una manera controlada, que comprende un portador polimérico biodegradable con el péptido regulador de la glucosa encapsulado en éste, y los métodos para la preparación de las mismas. Además, para asegurar la alta eficiencia de encapsulamiento y la alta estabilidad del fármaco encapsulado, las microesferas no muestran un efecto inicial rápida ni tampoco liberación incompleta, y permiten la liberación de orden cero de los fármacos en un periodo prolongado, mejorando de este modo el efecto terapéutico del fármaco.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20070038467 | 2007-04-19 | ||
PCT/KR2008/002216 WO2008130158A1 (en) | 2007-04-19 | 2008-04-18 | A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009011275A true MX2009011275A (es) | 2009-11-02 |
Family
ID=39875642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009011275A MX2009011275A (es) | 2007-04-19 | 2008-04-18 | Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma. |
Country Status (14)
Country | Link |
---|---|
US (1) | US8282990B2 (es) |
EP (1) | EP2139458A4 (es) |
JP (1) | JP5302952B2 (es) |
KR (2) | KR101034888B1 (es) |
CN (1) | CN101657190B (es) |
AU (1) | AU2008241699B2 (es) |
BR (1) | BRPI0810140A2 (es) |
CA (1) | CA2683698C (es) |
CO (1) | CO6241098A2 (es) |
IL (1) | IL201523A0 (es) |
MX (1) | MX2009011275A (es) |
NZ (1) | NZ580700A (es) |
RU (1) | RU2422134C1 (es) |
WO (1) | WO2008130158A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2411038B1 (en) | 2009-03-27 | 2016-12-28 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
WO2011032099A1 (en) | 2009-09-11 | 2011-03-17 | The Board Of Trustees Of The University Of Illinois | Methods of treating diastolic dysfunction and related conditions |
US20120208762A1 (en) | 2009-10-27 | 2012-08-16 | The Board Of Trustees Of The University Of Illinois | Methods of Diagnosing Diastolic Dysfunction |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
RU2012136450A (ru) | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
EP2547359B1 (en) | 2010-03-15 | 2016-03-09 | The Board of Trustees of the University of Illionis | Inhibitors of beta integrin-g protein alpha subunit binding interactions |
EP2582719B1 (en) | 2010-06-16 | 2016-08-10 | Indiana University Research and Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
CN102370624A (zh) * | 2010-08-17 | 2012-03-14 | 东莞太力生物工程有限公司 | Exendin-4缓释微球及其注射剂和该缓释微球的制备方法 |
US9675521B2 (en) | 2010-09-02 | 2017-06-13 | Nippon Kayaku Kabushiki Kaisha | Process for producing drug-block copolymer composite and pharmaceutical preparation containing same |
KR101785515B1 (ko) * | 2010-11-08 | 2017-10-16 | 에스케이케미칼주식회사 | 올란자핀 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물 |
KR20120048811A (ko) * | 2010-11-08 | 2012-05-16 | 에스케이케미칼주식회사 | 아나스트로졸 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물 |
EP2655401B1 (en) | 2010-12-20 | 2016-03-09 | The Regents of the University of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
MA34885B1 (fr) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | Analogues du glucagon presentant una ctivite de recepteur de gip |
LT2723367T (lt) | 2011-06-22 | 2017-08-25 | Indiana University Research And Technology Corporation | Bendri gliukagono/glp-1 receptoriaus agonistai |
WO2013055791A1 (en) | 2011-10-10 | 2013-04-18 | The Regents Of The University Of Michigan | Polymeric nanoparticles for ultrasound imaging and therapy |
WO2013074910A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
CN104114183A (zh) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
CN104619350A (zh) | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
AR091478A1 (es) | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa) |
RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
AU2013323669B2 (en) | 2012-09-26 | 2018-03-01 | Indiana University Research And Technology Corporation | Insulin analog dimers |
RU2678134C2 (ru) | 2013-03-14 | 2019-01-23 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты инсулин-инкретин |
KR101486132B1 (ko) * | 2013-03-20 | 2015-01-23 | 씨제이헬스케어 주식회사 | 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구 |
WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
WO2016123143A1 (en) | 2015-01-26 | 2016-08-04 | The University Of Chicago | CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2 |
US10308719B2 (en) | 2015-01-26 | 2019-06-04 | The University Of Chicago | IL13Rα2 binding agents and use thereof in cancer treatment |
WO2017024111A1 (en) | 2015-08-04 | 2017-02-09 | The University Of Chicago | Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6 |
WO2017053346A1 (en) | 2015-09-21 | 2017-03-30 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
KR101706254B1 (ko) * | 2015-11-17 | 2017-02-13 | 주식회사 동일팜텍 | 생체조직 수복 또는 재생용 고분자 미세입자의 제조방법 |
US10406336B2 (en) | 2016-08-03 | 2019-09-10 | Neil S. Davey | Adjustable rate drug delivery implantable device |
CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
WO2019006235A1 (en) | 2017-06-30 | 2019-01-03 | Amgen Inc. | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
EP3661954B1 (en) | 2017-08-03 | 2022-02-09 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
CN111565744A (zh) | 2017-09-18 | 2020-08-21 | 加利福尼亚大学董事会 | 紧密连接蛋白6抗体和治疗癌症的方法 |
KR102047983B1 (ko) | 2017-11-30 | 2019-11-22 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
CN111886031B (zh) * | 2018-01-10 | 2022-10-14 | G2G生物公司 | 含胶原蛋白肽的聚己内酯微球填充物及其制备方法 |
CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
KR102137786B1 (ko) * | 2018-07-19 | 2020-07-24 | 주식회사 아울바이오 | 주사제용 미립구의 제조방법 |
RU2696773C1 (ru) * | 2018-08-13 | 2019-08-06 | Алексей Николаевич Осинцев | Способ получения лекарственного препарата пептидной природы с контролируемым и последовательным высвобождением |
WO2020055913A1 (en) | 2018-09-10 | 2020-03-19 | Cardax, Inc. | Methods of reducing- c-reactive protein and/or treating cardiovascular disease |
WO2020191342A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
CA3136496A1 (en) | 2019-04-09 | 2020-10-15 | The Board Of Trustees Of The University Of Illinois | Drug adsorbed highly porous activated carbon for enhanced drug delivery |
US20230190725A1 (en) | 2019-04-29 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
CA3132656A1 (en) | 2019-04-30 | 2020-11-05 | Instituto De Medicina Molecular Joao Lobo Antunes | Rank pathway inhibitors in combination with cdk inhibitors |
CA3140904A1 (en) | 2019-06-24 | 2020-12-30 | Amgen Inc. | Inhibition of sirp-gamma for cancer treatment |
US20220280561A1 (en) | 2019-08-30 | 2022-09-08 | Research Institute At Nationwide Children's Hospital | Copper-atsm for treating neurodegenerative disorders associted with mitochondrial dysfunction |
KR102583029B1 (ko) * | 2020-05-28 | 2023-09-26 | 주식회사 아울바이오 | 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법 |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
KR102469409B1 (ko) * | 2020-08-24 | 2022-11-23 | 주식회사 메피온 | 색전물질 제조 방법 |
US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
CN114588115B (zh) * | 2022-04-20 | 2023-01-13 | 上海瑞凝生物科技有限公司 | 一种plga药物缓释微球的制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US5271961A (en) * | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
SE512663C2 (sv) * | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
ATE289205T1 (de) * | 1998-12-15 | 2005-03-15 | Takeda Pharmaceutical | Verfahren zur herstellung biologisch-abbaubarer polyester |
WO2001072323A2 (en) * | 2000-03-24 | 2001-10-04 | Genentech, Inc. | Use of insulin for the treatment of cartilagenous disorders |
EP1296660A4 (en) * | 2000-06-27 | 2005-04-13 | Mi Tech Company Ltd | PREPARATION FOR THE CONTROLLED RELEASE OF INSULIN AND ITS MANUFACTURING METHOD |
CA2432904C (en) * | 2000-12-21 | 2007-09-11 | Nektar Therapeutics | Induced phase transition method for the production of microparticles containing hydrophobic active agents |
JP2003212758A (ja) * | 2001-03-16 | 2003-07-30 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
EP1369130A1 (en) * | 2001-03-16 | 2003-12-10 | Takeda Chemical Industries, Ltd. | Process for producing sustained release preparation |
KR100566573B1 (ko) * | 2002-04-13 | 2006-03-31 | 주식회사 펩트론 | Lhrh 동족체를 함유하는 서방성 미립구의 제조방법 |
CN102935069A (zh) | 2003-07-15 | 2013-02-20 | Pr药品有限公司 | 控释组合物的制备方法 |
PT1734971E (pt) * | 2004-04-15 | 2012-02-02 | Amylin Pharmaceuticals Inc | Dispositivo de libertação sustentada baseado em polímero |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
-
2008
- 2008-04-18 AU AU2008241699A patent/AU2008241699B2/en not_active Ceased
- 2008-04-18 NZ NZ580700A patent/NZ580700A/en not_active IP Right Cessation
- 2008-04-18 KR KR1020080036189A patent/KR101034888B1/ko not_active IP Right Cessation
- 2008-04-18 CN CN2008800123273A patent/CN101657190B/zh not_active Expired - Fee Related
- 2008-04-18 JP JP2010503980A patent/JP5302952B2/ja not_active Expired - Fee Related
- 2008-04-18 EP EP08741460A patent/EP2139458A4/en not_active Withdrawn
- 2008-04-18 BR BRPI0810140-0A2A patent/BRPI0810140A2/pt not_active IP Right Cessation
- 2008-04-18 CA CA2683698A patent/CA2683698C/en not_active Expired - Fee Related
- 2008-04-18 US US12/595,434 patent/US8282990B2/en not_active Expired - Fee Related
- 2008-04-18 WO PCT/KR2008/002216 patent/WO2008130158A1/en active Application Filing
- 2008-04-18 RU RU2009142608/15A patent/RU2422134C1/ru not_active IP Right Cessation
- 2008-04-18 MX MX2009011275A patent/MX2009011275A/es active IP Right Grant
-
2009
- 2009-10-14 IL IL201523A patent/IL201523A0/en unknown
- 2009-11-19 CO CO09131818A patent/CO6241098A2/es not_active Application Discontinuation
-
2011
- 2011-04-13 KR KR1020110034213A patent/KR20110044192A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2422134C1 (ru) | 2011-06-27 |
CN101657190B (zh) | 2013-09-11 |
EP2139458A4 (en) | 2013-01-23 |
JP2010524924A (ja) | 2010-07-22 |
CA2683698A1 (en) | 2008-10-30 |
CO6241098A2 (es) | 2011-01-20 |
NZ580700A (en) | 2012-01-12 |
AU2008241699B2 (en) | 2011-02-03 |
IL201523A0 (en) | 2010-05-31 |
CA2683698C (en) | 2013-09-10 |
KR101034888B1 (ko) | 2011-05-17 |
EP2139458A1 (en) | 2010-01-06 |
AU2008241699A1 (en) | 2008-10-30 |
WO2008130158A1 (en) | 2008-10-30 |
US20100129459A1 (en) | 2010-05-27 |
BRPI0810140A2 (pt) | 2014-10-29 |
CN101657190A (zh) | 2010-02-24 |
US8282990B2 (en) | 2012-10-09 |
JP5302952B2 (ja) | 2013-10-02 |
KR20110044192A (ko) | 2011-04-28 |
KR20080094616A (ko) | 2008-10-23 |
RU2009142608A (ru) | 2011-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009011275A (es) | Una composicion de microesferas biodegradables adecuadas para la liberacion controlada de peptido de control de la glucosa y formulacion de la misma. | |
WO2010024615A3 (ko) | 용매교류증발법에 의한 서방출성 미립구의 제조방법 | |
CA2534997A1 (en) | Methods for administering aripiprazole | |
EP3492069A3 (en) | Pharmaceutical compositions | |
WO2006125819A3 (fr) | Forme medicamenteuse orale, microparticulaire, anti-mesusage | |
WO2004112756A8 (en) | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | |
MX2008012731A (es) | Tabletas de paracetamol de liberacion rapida. | |
BR0107874A (pt) | Implante farmacêutico para controlavelmente liberar uma droga, método para controlavelmente liberar uma droga em um indivìduo, e, método para preparar o implante | |
WO2006078811A3 (en) | Pharmaceutical formulations and methods of use | |
DE602008002073D1 (de) | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung | |
WO2009114614A3 (en) | Compositions and methods for controlled delivery of inhibitory ribonucleic acids | |
IL173965A (en) | Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell | |
IL195931A0 (en) | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production | |
ZA200900929B (en) | Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same | |
WO2007018588A8 (en) | Stable pharmaceutical composition comprising linezolid form iv | |
JP2010518086A5 (es) | ||
WO2008084504A3 (en) | Pharmaceutical compositions of angiotensin ii receptor blockers | |
WO2010027404A3 (en) | Stable formulation comprising therapeutic polypeptides for oral administration | |
WO2014106116A8 (en) | Therapeutic compositions comprising antibodies | |
WO2012053785A3 (ko) | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 | |
EP1753398A4 (en) | PHARMACEUTICAL DOSAGE FORMULATION COMPRISING A CONTROLLED RELEASE MATRIX | |
WO2012092486A3 (en) | Modified release benzimidazole formulations | |
WO2001013898A3 (en) | Pharmaceutical formulations with different release times | |
WO2012172433A3 (en) | A sustained -release composition containing a melanocortin receptor ligand as the active ingredient | |
GEP20125636B (en) | Slow-release formulation based on glycogen and alginate association |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |